- NASDAQ: APM ended Tuesday's session with a surge of 90% after hitting even higher levels.
- Shares then collapsed back below $3, completing a pump-and-dump move.
- Aptorum Group launched a new unit focused on an infectious disease liquid biopsy unit.
- Venturing into a new field involving the coronavirus implies strong growth for the low-valued company.
When a stock trades at rock-bottom levels, a small spark is all that is needed to trigger a surge. Aptorum Group Ltd nearly quadrupled in value in Tuesday's intense session, closing at $4.76 after already hitting a high of $14.23. Shares then collapsed back below $3 on a Wednesday session dominated by bears, taking the price back nearly to Monday's levels. On Thursday, trading action was quiet, with NASDAQ:APM closing at $2.89 after staying the whole session between $2.7 and $3.1.
After the recent leap and plunge, NASDAQ: APM's market capitalization is only $87.82 million. Can it rise?
APM Stock News
Aptorum jumped after announcing the launch of Aptorum Innovations, a subsidiary focused on infectious disease liquid biopsy diagnostics. When speaking of diseases that spread rapidly, SARS-Cov-2 – the virus behind COVID-19 – immediately comes to mind.
Indeed, Aptorum has in-licensed exclusive rights to develop novel molecular-based rapid pathogen identification and detection diagnostics (RPIDD) technology with a Singapore-based company called Accelerate Technologies PTE Ltd. The fir is the commercialization arm of the city-state's Agency for Science, Technology, and Research.
The collaboration with a firm backed by Singapore – a country that successfully battled the coronavirus, is inspiring investors.
While several COVID-19 vaccines are at a late stage, there is still room for those specializing in rapid identification of this coronavirus and potentially new ones that could appear in recent years. It is essential to note that the full mitigation of the original SARS disease from 2002-2003 was never fully achieved.
Broader markets are focused on the chaotic presidential debate – which veered away from the virus – yet its prominence is still critical for investors.
See Presidential Debate: Stocks set to suffer on Trump's refusal to accept the results
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.
Recommended content
Editors’ Picks
EUR/USD clings to daily gains above 1.0650
EUR/USD gained traction and turned positive on the day above 1.0650. The improvement seen in risk mood following the earlier flight to safety weighs on the US Dollar ahead of the weekend and helps the pair push higher.
GBP/USD recovers toward 1.2450 after UK Retail Sales data
GBP/USD reversed its direction and advanced to the 1.2450 area after touching a fresh multi-month low below 1.2400 in the Asian session. The positive shift seen in risk mood on easing fears over a deepening Iran-Israel conflict supports the pair.
Gold holds steady at around $2,380 following earlier spike
Gold stabilized near $2,380 after spiking above $2,400 with the immediate reaction to reports of Israel striking Iran. Meanwhile, the pullback seen in the US Treasury bond yields helps XAU/USD hold its ground.
Bitcoin Weekly Forecast: BTC post-halving rally could be partially priced in Premium
Bitcoin price shows no signs of directional bias while it holds above $60,000. The fourth BTC halving is partially priced in, according to Deutsche Bank’s research.
Week ahead – US GDP and BoJ decision on top of next week’s agenda
US GDP, core PCE and PMIs the next tests for the Dollar. Investors await BoJ for guidance about next rate hike. EU and UK PMIs, as well as Australian CPIs also on tap.